RT @HeitnerStephen: Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy | JACC: Journal of the…
RT @HeitnerStephen: Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy | JACC: Journal of the…
RT @HeitnerStephen: Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy | JACC: Journal of the…
Exciting times ahead...
Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy | JACC: Journal of the American College of Cardiology https://t.co/YCI6cjkuCO
RT @jvillacastin: Nuevos fármacos inhibidores de la miosina, parecen bien tolerados y disminuyen bio marcadores sanguíneos en pacientes con…
Exciting to have the MAVERICK Phase 2 data published in JACC! Congratulations to all investigators and thank you to the participants with nHCM. Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy https://t.co
RT @jvillacastin: Nuevos fármacos inhibidores de la miosina, parecen bien tolerados y disminuyen bio marcadores sanguíneos en pacientes con…
RT @jvillacastin: Nuevos fármacos inhibidores de la miosina, parecen bien tolerados y disminuyen bio marcadores sanguíneos en pacientes con…
RT @MyoKardia: Online in @JACCJournals: Results from MAVERICK-HCM show that mavacamten is well tolerated in most individuals with non-obstr…
RT @jvillacastin: Nuevos fármacos inhibidores de la miosina, parecen bien tolerados y disminuyen bio marcadores sanguíneos en pacientes con…
RT @jvillacastin: Nuevos fármacos inhibidores de la miosina, parecen bien tolerados y disminuyen bio marcadores sanguíneos en pacientes con…
RT @jvillacastin: Nuevos fármacos inhibidores de la miosina, parecen bien tolerados y disminuyen bio marcadores sanguíneos en pacientes con…
RT @jvillacastin: Nuevos fármacos inhibidores de la miosina, parecen bien tolerados y disminuyen bio marcadores sanguíneos en pacientes con…
RT @jvillacastin: Nuevos fármacos inhibidores de la miosina, parecen bien tolerados y disminuyen bio marcadores sanguíneos en pacientes con…
RT @jvillacastin: Nuevos fármacos inhibidores de la miosina, parecen bien tolerados y disminuyen bio marcadores sanguíneos en pacientes con…
RT @jvillacastin: Nuevos fármacos inhibidores de la miosina, parecen bien tolerados y disminuyen bio marcadores sanguíneos en pacientes con…
RT @jvillacastin: Nuevos fármacos inhibidores de la miosina, parecen bien tolerados y disminuyen bio marcadores sanguíneos en pacientes con…
Nuevos fármacos inhibidores de la miosina, parecen bien tolerados y disminuyen bio marcadores sanguíneos en pacientes con miocardiopatía hipertrófica. Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy https:/
RT @MyoKardia: Online in @JACCJournals: Results from MAVERICK-HCM show that mavacamten is well tolerated in most individuals with non-obstr…
RT @MyoKardia: Online in @JACCJournals: Results from MAVERICK-HCM show that mavacamten is well tolerated in most individuals with non-obstr…
RT @MyoKardia: Online in @JACCJournals: Results from MAVERICK-HCM show that mavacamten is well tolerated in most individuals with non-obstr…
Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy | JACC: Journal of the American College of Cardiology https://t.co/jnPUTBd5Zx
RT @MyoKardia: Online in @JACCJournals: Results from MAVERICK-HCM show that mavacamten is well tolerated in most individuals with non-obstr…
RT @MyoKardia: Online in @JACCJournals: Results from MAVERICK-HCM show that mavacamten is well tolerated in most individuals with non-obstr…
RT @MyoKardia: Online in @JACCJournals: Results from MAVERICK-HCM show that mavacamten is well tolerated in most individuals with non-obstr…
RT @MyoKardia: Online in @JACCJournals: Results from MAVERICK-HCM show that mavacamten is well tolerated in most individuals with non-obstr…
RT @MyoKardia: Online in @JACCJournals: Results from MAVERICK-HCM show that mavacamten is well tolerated in most individuals with non-obstr…
@JACCJournals Non-obstructive Hypertrophic Cardiomyopathy #HCM
Online in @JACCJournals: Results from MAVERICK-HCM show that mavacamten is well tolerated in most individuals with non-obstructive #HCM. Read more about this study: https://t.co/VmASS2Gegg #cardiotwitter https://t.co/a3MtzLmA5S
RT @MasriAhmadMD: #MAVERICK paper is out in @JACCJournals Mavacamten in non-obstructive #HCM Congrats @HeitnerStephen @CarolynHoMD @Danie…
RT @MasriAhmadMD: #MAVERICK paper is out in @JACCJournals Mavacamten in non-obstructive #HCM Congrats @HeitnerStephen @CarolynHoMD @Danie…
RT @MasriAhmadMD: #MAVERICK paper is out in @JACCJournals Mavacamten in non-obstructive #HCM Congrats @HeitnerStephen @CarolynHoMD @Danie…
RT @CardiologyClub: Have you heard of #mavacamten for patients with #nHOCM 📣 Check this: https://t.co/kewdaWhlVR
Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy | JACC: Journal of the American College of Cardiology https://t.co/gUvIgryeeq
RT @MasriAhmadMD: #MAVERICK paper is out in @JACCJournals Mavacamten in non-obstructive #HCM Congrats @HeitnerStephen @CarolynHoMD @Danie…
RT @MasriAhmadMD: #MAVERICK paper is out in @JACCJournals Mavacamten in non-obstructive #HCM Congrats @HeitnerStephen @CarolynHoMD @Danie…
Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy | JACC: Journal of the American College of Cardiology : Myosin inhibition improves surrogate biomarker outcomes ; a glimpse of hope for phase 3 https://t.co/f
RT @MasriAhmadMD: #MAVERICK paper is out in @JACCJournals Mavacamten in non-obstructive #HCM Congrats @HeitnerStephen @CarolynHoMD @Danie…
RT @MasriAhmadMD: #MAVERICK paper is out in @JACCJournals Mavacamten in non-obstructive #HCM Congrats @HeitnerStephen @CarolynHoMD @Danie…
RT @MasriAhmadMD: #MAVERICK paper is out in @JACCJournals Mavacamten in non-obstructive #HCM Congrats @HeitnerStephen @CarolynHoMD @Danie…
RT @MasriAhmadMD: #MAVERICK paper is out in @JACCJournals Mavacamten in non-obstructive #HCM Congrats @HeitnerStephen @CarolynHoMD @Danie…
Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy https://t.co/vB3FERfB1Z
RT @MasriAhmadMD: #MAVERICK paper is out in @JACCJournals Mavacamten in non-obstructive #HCM Congrats @HeitnerStephen @CarolynHoMD @Danie…
RT @MasriAhmadMD: #MAVERICK paper is out in @JACCJournals Mavacamten in non-obstructive #HCM Congrats @HeitnerStephen @CarolynHoMD @Danie…
RT @MasriAhmadMD: #MAVERICK paper is out in @JACCJournals Mavacamten in non-obstructive #HCM Congrats @HeitnerStephen @CarolynHoMD @Danie…
RT @MasriAhmadMD: #MAVERICK paper is out in @JACCJournals Mavacamten in non-obstructive #HCM Congrats @HeitnerStephen @CarolynHoMD @Danie…
RT @MasriAhmadMD: #MAVERICK paper is out in @JACCJournals Mavacamten in non-obstructive #HCM Congrats @HeitnerStephen @CarolynHoMD @Danie…
RT @MasriAhmadMD: #MAVERICK paper is out in @JACCJournals Mavacamten in non-obstructive #HCM Congrats @HeitnerStephen @CarolynHoMD @Danie…
RT @MasriAhmadMD: #MAVERICK paper is out in @JACCJournals Mavacamten in non-obstructive #HCM Congrats @HeitnerStephen @CarolynHoMD @Danie…
Mavacamten, a small molecule inhibitor of B-myosin ATPase shows promise in patients with #HCM (decreased NTpBNP and cTnI) - nice work by Carolyn Ho @BrighamResearch et al! https://t.co/P6p9xP2sug
RT @MasriAhmadMD: #MAVERICK paper is out in @JACCJournals Mavacamten in non-obstructive #HCM Congrats @HeitnerStephen @CarolynHoMD @Danie…
RT @MasriAhmadMD: #MAVERICK paper is out in @JACCJournals Mavacamten in non-obstructive #HCM Congrats @HeitnerStephen @CarolynHoMD @Danie…
#MAVERICK paper is out in @JACCJournals Mavacamten in non-obstructive #HCM Congrats @HeitnerStephen @CarolynHoMD @DanielJacobyMD @S2beri @TimWong_MD et al https://t.co/93kMnN952J #cardiotwitter https://t.co/qthy7puPvf
RT @CardiologyClub: Have you heard of #mavacamten for patients with #nHOCM 📣 Check this: https://t.co/kewdaWhlVR
Exciting news for patients with Hypertrophic Cardiomyopathy. Here's to hoping for the best in MAVERICK-HCM when clinical outcomes are reported!!! Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy https://t.co
肥大型心筋症に対するミオシン阻害薬の有効性を示唆した無作為化比較試験。 Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy https://t.co/6lxGzPPoPO
Have you heard of #mavacamten for patients with #nHOCM 📣 Check this: https://t.co/kewdaWhlVR